July 29, 2008 - Not all parts of a tumor respond to radiation therapy in the same way.

Treatments in the future may target the most resistant tumor regions, but measuring this resistance is far from straightforward, a new analysis shows.

Common radiation therapy prescribes a uniform radiation dose to the entire tumor, even though it is commonly known that some regions resist radiation more than others. Researchers are therefore experimenting with ways to tailor the treatment, with so-called "dose painting," so that more radiation falls on the radio-resistant parts.

For this to be effective, radio-resistance must be well-defined at the molecular level. This presumably can be done with PET scans using the radio-tracer FLT (fluoro-L-thymidine). When injected into the body, FLT is grabbed up by cells in the process of cell division. Therefore, rapidly-dividing cancer cells will look bright in a PET scan. Once treatment is started, those cells that remain bright would be considered radio-resistant (i.e. the radiation is not affecting their activity.) But this simple brightness measure, called a standardized uptake value (SUV), is not the only way to locate non-responsive cells in a PET image. A more precise way (based on a parameter called KFLT) is to model how the radio-tracer travels through the body and is taken up by cells over time.

Urban Simoncic of the Institut Jozef Stefan in Ljubljana, Slovenia, together with collaborators from University of Wisconsin-Madison compared the SUV and KFLT techniques on the exact same sets of PET scans and found that the two selected out different regions as being radio-resistant. This implies that a dose painting treatment based on one model would differ significantly from that based on the other. The researchers believe the community needs to address this discrepancy with more careful clinical investigation.

For more information: www.aapm.org

Source: American Association of Physicists in Medicine


Related Content

News | Artificial Intelligence

May 2, 2024 — Radformation, Inc., a leader in automation solutions for cancer care, announced today that it has acquired ...

Time May 02, 2024
arrow
News | Prostate Cancer

May 2, 2024 — GT Medical Technologies, Inc. (GT MedTech), a medical device company with the mission of improving the ...

Time May 02, 2024
arrow
News | FDA

April 29, 2024 — The U.S. Food and Drug Administration (FDA) announced Elekta Instrument AB is recalling Disposable ...

Time April 29, 2024
arrow
News | Radiation Dose Management

April 25, 2024 — BIOTRONIK, a leading global medical technology company specializing in innovative cardiovascular and ...

Time April 25, 2024
arrow
News | Artificial Intelligence

March 28, 2024 — As artificial intelligence (AI) makes its way into cancer care – and into discussions between ...

Time March 28, 2024
arrow
News | Prostate Cancer

March 27, 2024 — A minimally invasive treatment using MRI and transurethral ultrasound instead of surgery or radiation ...

Time March 27, 2024
arrow
Videos | Radiation Oncology

In the conclusion of this 3-part video series on recent advancements in diagnostic radiology, current editorial advisory ...

Time March 19, 2024
arrow
News | Breast Imaging

March 18, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time March 18, 2024
arrow
Feature | Radiation Oncology | By Christine Book

Appreciating the considerable advances in the clinical application of artificial intelligence (AI) within healthcare ...

Time March 06, 2024
arrow
News | FDA

March 1, 2024 — Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S ...

Time March 01, 2024
arrow
Subscribe Now